Aims: The objectives of the study were to determine whether body mass index (BMI), and oral corticosteroid use predict survival and hospitalization in hypoxaemic chronic obstructive pulmonary disease (COPD) patients. Methods: The study was a prospective cohort study with analysis of a nationwide database (Danish Oxygen Register). We studied survival and hospitalization in 221 hypoxaemic COPD patients who were on long-term oxygen therapy (LTOT). Results: Low BMI was strongly associated with high mortality (P < 0.001). Maintenance treatment with steroids was only associated with higher mortality in overweight patients (BMI > 25 kg/mi2), RR = 3.8 (1.4-10.5), P = 0.011. Whereas BMI had no influence on risk of any hospitalization in patients using oral steroids, high BMI was independently associated with reduced risk of any hospitalization in patients without oral steroids [the RR of any hospitalization for each 1 kg/M2 increase in BMI was 0.94 (CI: 0.90-0.99), P = 0.009]. Overall, the use of oral steroids was associated with increased risk of any hospitalization, RR = 1.7 (1.2-2.4), P = 0.002. This increase was especially pronounced in the group with BMI above 25 kg/M2, where steroid treatment increased the risk of any hospitalization with RR = 3.6 (1.5-8.7), P = 0.005. Conclusions: In hypoxaemic patients on LTOT, low BMI is an independent risk factor of death and any hospitalization. Maintenance treatment with oral corticosteroids is associated with increased mortality and hospitalization in COPD patients with high BMI. Our findings suggest that loss of body weight should be avoided, and that oral corticosteroids should be used cautiously in patients on LTOTespecially those with high BMI. Further research on the role of changes in body composition as a prognostic factor is needed. Chronic Respiratory Disease 2004; 1: 71-78
Weight loss and in particular loss of skeletal muscle mass has long been recognized as a feature of advanced chronic obstructive pulmonary disease (COPD). Recent studies of COPD patients without severe hypoxaemial5 and a single study of COPD patients with severe hypoxaemia on long-term oxygen therapy (LTOT)6 have shown that low body mass index (BMI) is an independent predictor of poor survival. The ANTADIR study also examined the relationship between BMI and hospitalization in COPD patients on LTOT. 6 The investigators found that low BMI was a powerful predictor of rate and duration of hospitalization.6 Unfortunately, they were not able to include smoking status, compliance with administration of oxygen, oral corticosteroid treatment, and performance status in the analysesall factors that are considered to influence prognosis in these patients. [6] [7] [8] Although it is not recommended, patients with severe COPD are often treated with continuous oral corticosteroids. 9 In the Swedish study of patients on LTOT, oral steroid treatment was associated with increased mortality and hospitalization among females with COPD;7 however, BMI was not accounted for.
In the present prospective study, we investigated the role of BMI, and oral corticosteroid treatment as independent predictors of survival and hospitalization in hypoxaemic COPD patients on LTOT.
Methods
tensions. I plemental o Data sources month befo months aft We used the data from the Danish Oxygen Register, LTOT, the r which was established in November 1994 and covers use of oxyg 98% of the Danish population. The study comprised (yes/no), h( 221 COPD patients with hypoxaemia and known BMI scale: score (Figure 1 ). Vital status was ascertained by the National restricted in Health Services Central Register up to 31 July 2000. part of, up In the survival analyses, the mean follow-up time was hours; 3, cc 4.9 years (range, 0.3-5.8 years) and 147 (66.5%) hours; 4, to deaths were observed. The National Board of Health In our al provided information on all hospital admissions in the BMI and i follow-up period. A total of204 (92.3%) patients had at index was( least one hospitalization within the mean follow-up (less than 2 period of 2.6 years (range, 0.2-5.7 years). Only and overwe 15 patients stopped oxygen therapy without having at categories N least one hospitalization (nine patients died and comparison six stopped due to other reasons). None of the in Referen patients had been treated with home mechanical into two cl ventilation, anabolic steroids, or underwent pulmonary oral cortic rehabilitation or lung surgery during the study prescribed period. The regional Ethical Committees and the the treatme Data Inspection Board have approved the present general imi study.
during stab From patients' hospital files and general practitioner and theref files, we obtained information on diagnosis, medical (SD = 10.7 treatment (including oral and inhaled corticosteroid) all the med during the first 6-12 months of LTOT, smoking habits, COPD an ECG, weight, height, FEV1, and arterial blood gas hypoxaemi; Fhe best arterial blood test without supxygen and obtained within the period of one re initiation of LTOT was registered to three ter. Within one month after initiation of patients received a questionnaire by mail on )en (number of hours daily), outdoor activity ieight, weight, and WHO performance status e 0; able to carry out normal activity; 1, i activity, but ambulatory; 2, confined to bed iand about for more than 50% of waking )nfined to bed for more than 50% of waking tally confined to bed. nalyses, the variables of main interest were oral corticosteroid treatment. Body mass categorized into three groups: underweight kg/M2), normal weight (20-24.9 kg/M2), ight/obesity (25 kg/M2 and above). These were defined arbitrarily and chosen to make iwith other studies, such as those described wces 3 and 6. Patients were classified ,ategories according to use of continuous osteroids (yes/no). If the patients were oral steroid without intention of stopping, .nt was defined as 'continuous' -this in plied an oral steroid dose of 5-10 mg daily )le periods. All patients had severe COPD fore reduced FEVy, on average 29.8% 7) of predicted. One of the authors checked lical files to ensure that all the patients had Id that this was the main cause of a.
Excluded COPD patients with infonnation on BMI and oral corticosteroids Statistical analyses
Cox regression model was used to determine whether BMI, and use of systemic glucocorticoids were individual predictors of survival and hospitalization. Covariates in the multivariate models were as follows: gender, hours spent with oxygen according to the patient (continuous variable), oxygen flow (continuous variable), PaO2 on room air (continuous variable), PaCO2 on oxygen (continuous variable), age (continuous variable), outdoor activity (yes or no), current smoking (yes or no), inhaled corticosteroids (yes or no), PaCO2 on room air (three groups: <46.9, 46.9-54.0, > 54.0 mmHg), PaO2 on oxygen (three groups: <60.0, 60.0-71.3, >71.3 mmHg), and WHO performance status scale (score 1-5). PaCO2 on room air and PaO2 on oxygen were divided into tertiles as listed above because linearity was not present. Assumption of linearity was assessed by categorizing the variable into multiple dichotomous variables of equal units on the variable's scale. The estimated coefficients of each dichotomous variable were compared. All covariates were tested for interaction with BMI and corticosteroid treatment. The hazard ratios for BMI and oral steroids were adjusted for those covariates (confounders) that were related to outcome (time to death or hospitalization, separately) and to the independent variable (BMI or treatment with oral steroids). Age and gender was forced into the model. Including FEV1% predicted value in the analysis did not change our findings. The results of regression analyses are given in terms of estimated relative risks (RRs) (hazard ratios), with corresponding 95% confidence intervals (CIs). Analyses were carried out on all patients, and on patients with and without continuous oral steroids, separately. Data analysis and descriptive statistics were performed with the statistical package for the social sciences (SPSS) version 11.0 (SPSS Inc., Chicago, USA). Nominal variables and ratio/interval variables were compared using X test and Mann-Whitney test or ANOVA, respectively. A two-sided P-value of < 0.05 was considered to be statistically significant. Table 1 . A total of 76 (34.4%) received continuous oral steroid treatment and 87 (39.4%) received inhaled corticosteroids. Pafients on oral steroids had less frequently low BMI (< 20 kg/m2) (23.7 versus 40.0%, P = 0.01), but their average BMI was not different from patients without oral steroid therapy, and there was no statistical difference for any of the other studied variables. Patients with low BMI had a slightly worse FEV1, were more often females, and reported less often outdoor activities and high performance score. On average, the reported utility of oxygen was 15.0 hours (SD = 6.3) daily, and the oxygen flow was 1.3 L/ minute (SD = 0.6). The use of oxygen and flow rates prescribed were not different between any of the BMI groups selected.
Results

Characteristics of the 221 patients at initiation of LTOT are shown in
Influence of BMI on survival
Body mass index was a strong independent predictor of survival. The relative risk (RR) of death for each 1 kg/in2 increase in BMI was 0.92 (CI: 0.88-0.95), P < 0.001, and correspondingly, Table 2 shows increased risk of dying in patients with BMI less than 20 kg/m2. The BMI exceeded 30 kg/mi2 in only 16 patients. Compared to patients with mild overweight (BMI, 25-30 kg/mi2), the risk of dying in these obese patients tended to be lower, 0.7 (0.3-1.9). The five-year survival rates were 24, 33 and 55%, respectivel', for patients with BMIs < 20, 20-24.9 and > 25 kg/m .
Influence of oral corticosteroids on survival
Comprising all patients, the Cox regression model showed that treatment with oral steroids did not affect the survival significantly, RR = 1.2 (95% CI: 0.9-1.7), P = 0.29. However, among the patients with BMI above 25 kg/M2, continuous treatment with oral steroid was associated with the RR of dying of 3.8 (1.4-10.5), P = 0.011 (Table 3) . Thus, oral steroids modified the association between BMI and mortality, having no effect on low and normal BMI and a detrimental effect on high BMI.
Influence of BMI on hospitalization
Cox regression analysis comprising all patients showed that BMI above 25 kg/M2 tended to decrease risk of any hospitalization compared with patients with a normal BMI (20-24.9 kg/m2), RR = 0.7 (0.5-1.0), P = 0.059 (Table 4 ). Whereas BMI had no influence on risk of hospitalization in patients using oral steroids, high BMI was independently associated with reduced risk of hospitalization in patients without oral steroids (the RR of any hospitalization for each 1 kg/M2 increase in BMI was 0.94 (CI: 0.90-0.99), P = 0.009).
Influence of oral corticosteroids on hospitalization
In the analysis of all patients, use of continuous oral steroids was associated with increased risk of any www.CRDjournal.com Among patients with BMI above 25 kg/mr2, oral steroid treatment increased the risk of any hospitalization even more, RR = 3.6 (1.5-8.7), P = 0.005 ( Table 5 ).
Influence of BMI and oral corticosteroids on mortality and hospitalization in the COPD patients without information on all covariates
Information on BMI and oral steroids was available in 281 of the 601 excluded COPD patients (Figure 1 ). Compared to the study group of 221 patients, these 281 patients had high one-month and one-year mortalities (13.2 and 38.8% versus 1.4 and 20.8%). In this group, the influence of BMI and steroids on mortality and hospitalization was similar to the findings among the 221 patients with information on all covariates ( Table 6 ).
Discussion
The Swedish Oxygen Register, The Polish Oxygen Group, the MRC study, and the NOTT study have provided data on predictors of survival in hypoxaemic COPD, but none of them have focused on nutritional status or body composition.7'8,10"11
In accordance with the ANTADIR study, we found that low BMI was an independent risk factor for mortality.6 The RR of death for each 5 kg/M2 increase in BMI was 0.75 in the French study and is 0.71 in our study. Similarly, the five-year survival rates for the BMI classes '<20' and '20-24.9' were identical, but due to a higher number of patients with low BMI in our study, the median survival was only 2.5 years compared to 3.5 years in the ANTADIR study. In contrast to the French study where about 86% of the patients were males, slightly more than half of our patients were females. In addition, these two studies differ with regard to selection of the patients: our study comprises all patients within a defined small geographical area, whereas the French study includes a small fraction of patients on LTOT in most ofFrance. The strength of our study is inclusion of a large number of potential confounders. Exclusion of LTOT patients with lack of some potential confounders seemed not to influence our results. Limitations of the present study must also be considered.
Our patients with recently measured FEV1 represent a group with a very narrow span of FEV1, which may explain the lack of association between FEVy and prognosis. Owing to a relatively low number of patients Chronic Respiratory Disease with high BMI in our study, it was not possible to determine the optimal BMI in respect of survival and hospitalization. However, in accordance with studies of nonhypoxaemic patients and the ANTADIR study, our study supports the notion that COPD patients with high BMI, including those with BMI > 30 kg/M2, seem to have the best survival.36
Several hypotheses explaining poor survival among the undernourished patients have been put forward, such as respiratory muscle weakness, 12-14 impaired gas exchange,15-7 and impaired immune response.18
Prospective randomized studies with nutritional support are needed to clarify whether the relationship between low BMI and poor prognosis is causal. So far only one study has indicated an effect of nutritional support on mortality.4 As suggested by Landbo et al., obesity in itself contributes to impaired gas exchange, indicating that obese subjects needing LTOT may not in fact have experienced as severe pulmonary destruction as the thin ones, and may therefore have a survival corresponding to that of individuals with less severe pulmonary disease. 3 The percentage of patients on oral steroid treatment in our study is remarkably high, but The Swedish Oxygen Register has reported an even higher frequency, 51%. 7 We found a tendency towards continuous corticosteroids being associated with an increased risk of death, but this was not significant. Thus we were not able to confirm the Swedish findings that oral corticosteroid treatment is associated with increased mortalityeven after stratification for gender.7 However, we found that mortality was higher in steroid-treated patients with BMI above 25 kg/M2.
In patients without LTOT, oral steroid treatment is clearly associated with increased mortality.19-22 Two population-based cohort studies of COPD patients have found that oral corticosteroids were associated with a significantly increased mortality, with relative risks of 1.3720 and 1.59. 19 Schols and coworkers showed that oral corticosteroids were associated with increased mortality in a dose-dependent manner. 22 Recently, a prospective Dutch study by the same study group of mortality-related factors after hospitalization for acute exacerbation of COPD found that use of oral steroids was associated with an increased risk of dying (RR = 5.07). 21 Table 6 Influence of BMI and oral corticosteroids on mortality and time to first hospitalization in 281 COPD patients excluded from the study group due to lack of data on potential confounders presented as crude relative risks (RR) with 95% confidence intervals (CI) and P-levels prescription of oral steroids, for example the patient's and prescribing doctor's attitudes to oral steroids. Our information on dose of oral steroid is not optimal and limited to the first 6-12 months on LTOT. Prolonged treatment with oral corticosteroids has numerous and significant side effects. 23 In patients with hypercapnic respiratory failure, corticosteroid-induced myopathy has been associated with increased mortality. 24 Most of our patients had hypercapnia, but high PaCO2 was not related to treatment with corticosteroid. In our study, use of oral steroids did only affect survival in patients with high BMI, and by that, it modified the association between BMI and survival: the strongest association between low BMI and poor survival was observed among patients without steroid treatment. This effect modification of steroid has not been reported previously. Oral corticosteroids affect body composition by decreasing muscle mass and increasing fat deposition and BMI. Muscle weakness (and use of steroids) contributes to utilization of health resources, 25 and peripheral muscle strength as well as skeletal muscle atrophy were shown to be significant determinants of survival in nonhypoxaemic COPD 24, 2 patients. 26 Moreover, it has been suggested that muscle mass and fat free mass (FFM) are a better predictor of physical impairmentl2,13 and mortality26 than BMI. Therefore, BMI could be a surrogate of another prognostic factor, that is, muscle mass or FFM; and in patients using oral corticosteroids, BMI could be less strongly associated with mortality and hospitalization. Body composition is not measured with BMI,12 and loss of FFM in the presence of normal or high BMI is possible and might be the mechanism behind the poorer prognosis in those with high BMI using steroids.
Although we have excluded patients with known concomitant malignant disease, confounding by other diseases affecting both BMI and mortality is a possibility. Concomitant diabetes mellitus or cardiovascular disease may, especially among the corticosteroid-treated patients, affect both BMI and mortality. This may be another explanation for the weaker association between BMI and survival observed in the corticosteroid-treated groups compared to those without corticosteroids.
We found that low BMI was an independent risk factor of hospitalization, although the influence of BMI on hospitalization was weaker than on survival and only significant among patients without oral steroids. The ANTADIR study showed similar association between hospitalization and BMI.6 In contrast to the ANTADIR study, we evaluate time until first hospitalization in all patients, while they studied duration and rate of hospitalization in those patients who survived at least one year. Furthermore, in the ANTADIR study, use of oral corticosteroids was not taken into account. Two studies of nonhypoxaemic COPD patients have shown an association between malnutrition and hospitalization. In a study of 39 COPD patients, poor nutritional status expressed as reduced triceps skinfold was associated with hospitalization,27 and in another study, lean mass depletion and weight loss were associated with early readmission. 28 Like the studies by Strom, Sin and Groenwegen, our study shows that continuous oral corticosteroids were associated with increased hospitalization.7'20 '21 In contrast to the Swedish study, this relationship was present in both genders. The reason for increased hospitalization has not been explored, but could be the well-known side effect of oral steroids. The beneficial influence of high BMI on hospitalization tended to be weaker among those using continuous oral corticosteroids than among those without this treatment. This indicates that we should be more cautious about treating these patients with high BMI with continuous oral corticosteroids, as they may be more prone to side effects of this treatment.
We conclude that in hypoxaemic COPD patients on LTOT, low BMI is an independent risk factor of death and any hospitalizationparticularly in those without oral corticosteroids. Treatment with oral corticosteroids increases mortality and hospitalization in patients with high BMI. Our findings suggest that underweight should be prevented, and that oral corticosteroids should be used cautiously in COPD patients on LTOT especially in those with high BMI. Further research on the role of changes in body composition as a prognostic factor in COPD is needed.
